Case Report: AFP-producing gastric hepatoid adenocarcinoma with multiple liver metastases - integrating quantitative imaging and diagnostic decision analysis.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: gastric lesions are essential for optimal management of this aggressive malignancy
I · Intervention 중재 / 시술
Billroth II gastrectomy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] This case illustrates the utility of quantitative CT enhancement analysis for characterizing the hypervascular phenotype of AFP-producing HAS and proposes a conceptual diagnostic framework to differentiate HAS from HCC. Multidisciplinary collaboration and systematic serum AFP screening in patients with gastric lesions are essential for optimal management of this aggressive malignancy.
[BACKGROUND] Hepatoid adenocarcinoma of the stomach (HAS) is a rare and aggressive gastric cancer variant with both glandular and hepatocellular differentiation.
APA
Zhong SY, Deng XR, et al. (2026). Case Report: AFP-producing gastric hepatoid adenocarcinoma with multiple liver metastases - integrating quantitative imaging and diagnostic decision analysis.. Frontiers in oncology, 16, 1768282. https://doi.org/10.3389/fonc.2026.1768282
MLA
Zhong SY, et al.. "Case Report: AFP-producing gastric hepatoid adenocarcinoma with multiple liver metastases - integrating quantitative imaging and diagnostic decision analysis.." Frontiers in oncology, vol. 16, 2026, pp. 1768282.
PMID
41959928
Abstract
[BACKGROUND] Hepatoid adenocarcinoma of the stomach (HAS) is a rare and aggressive gastric cancer variant with both glandular and hepatocellular differentiation. The AFP-producing subtype is strongly associated with early liver metastasis and poor prognosis, presenting significant diagnostic challenges due to its resemblance to hepatocellular carcinoma (HCC).
[CASE SUMMARY] A 68-year-old male presented with progressive dizziness and fatigue. Initial contrast-enhanced abdominal CT revealed a hypervascular gastric antral mass with quantitative enhancement values of 52 ± 3 HU (arterial), 78 ± 5 HU (portal), and 85 ± 4 HU (delayed) in the submucosal layer. Serum AFP was markedly elevated at 918.88 ng/mL. Gastroscopic biopsy confirmed AFP-producing HAS. The patient underwent Billroth II gastrectomy. Four months postoperatively, surveillance CT identified multiple new hypervascular liver metastases, prompting right hepatectomy followed by adjuvant radiochemotherapy. At three-month follow-up, the patient was asymptomatic with normalized tumor markers.
[CONCLUSION] This case illustrates the utility of quantitative CT enhancement analysis for characterizing the hypervascular phenotype of AFP-producing HAS and proposes a conceptual diagnostic framework to differentiate HAS from HCC. Multidisciplinary collaboration and systematic serum AFP screening in patients with gastric lesions are essential for optimal management of this aggressive malignancy.
[CASE SUMMARY] A 68-year-old male presented with progressive dizziness and fatigue. Initial contrast-enhanced abdominal CT revealed a hypervascular gastric antral mass with quantitative enhancement values of 52 ± 3 HU (arterial), 78 ± 5 HU (portal), and 85 ± 4 HU (delayed) in the submucosal layer. Serum AFP was markedly elevated at 918.88 ng/mL. Gastroscopic biopsy confirmed AFP-producing HAS. The patient underwent Billroth II gastrectomy. Four months postoperatively, surveillance CT identified multiple new hypervascular liver metastases, prompting right hepatectomy followed by adjuvant radiochemotherapy. At three-month follow-up, the patient was asymptomatic with normalized tumor markers.
[CONCLUSION] This case illustrates the utility of quantitative CT enhancement analysis for characterizing the hypervascular phenotype of AFP-producing HAS and proposes a conceptual diagnostic framework to differentiate HAS from HCC. Multidisciplinary collaboration and systematic serum AFP screening in patients with gastric lesions are essential for optimal management of this aggressive malignancy.